BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales

BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced positive blinded data from its Phase 2 clinical trial assessing hypoxic-cultured mesenchymal stem cells for chronic lumbar disc disease. The results indicated that 50% or more of patients reported over 50% improvement in key pain and function scales, with no adverse events related to dose-limiting toxicities. The efficacy endpoint for the trial was a greater than 30% improvement in the Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) at 52 weeks, highlighting the potential of this treatment for a significant unmet medical need.